Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 10, 2015
Event: Final closing of a private placement offering of units to accredited investors.
Key Financial Metrics
- Gross Proceeds: $10,000,000 from the sale of 20,000,000 Units.
- Net Proceeds: Approximately $8.5 million after deducting placement agent fees and estimated offering expenses.
- Unit Price: $0.50 per Unit.
- Unit Composition: One share of Common Stock and one five-year warrant to purchase one share of Common Stock at an exercise price of $0.75.
- Placement Agent Fees: $1,000,000 cash fee plus a $300,000 non-accountable expense allowance.
- Placement Agent Warrants: Warrants to purchase 2,000,000 shares at $0.50 and 2,000,000 shares at $0.75.
Note: This filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the increase in equity capital and the issuance of new securities:
- Equity Issuance: 20,000,000 shares of Common Stock issued immediately.
- Dilution Potential: 20,000,000 warrants issued to investors plus 4,000,000 warrants issued to the placement agent.
- Liquidity Impact: Significant infusion of cash intended for research and development and working capital.
Guidance, Outlook, and Risks
- Use of Proceeds: Funds will be used to fund research and development and for working capital and general corporate purposes.
- Registration Rights: The Company must file a registration statement within 60 days covering the resale of shares underlying the offering.
- Warrant Call Provision: Warrants are callable if the closing bid price is at or above $3.00 per share for 20 consecutive trading days, provided the registration statement is current.
- Related Party Transactions: The placement agent (Aegis Capital Corp.) and its affiliates owned more than 10% of outstanding equity prior to the offering. A member of the placement agent's firm sits on the Company's board of directors. Board members and management participated in the offering.
- Restrictions: Securities were issued under Section 4(a)(2) and Rule 506(b) exemptions and are restricted under Rule 144.
Investor Verification Checklist
- Verify the exact number of outstanding shares post-closing to assess dilution impact.
- Confirm the filing of the registration statement within the required 60-day window.
- Review the Company's cash burn rate to determine how long the $8.5 million net proceeds will sustain operations.
- Monitor the stock price relative to the $3.00 warrant call threshold.
- Check for any subsequent filings regarding the specific allocation of proceeds to R&D projects.